BIOTECH WALLAH PRIVATE LIMITED

In their own words

Biotech Wallah Pvt. Ltd. is a DeepTech startup at the intersection of Artificial Intelligence, Biotechnology, and Healthcare, focused on transforming the drug discovery process. Today, drug development is slow, expensive, and risky—taking over 10–15 years and costing upwards of $2 billion, with nearly 90% of candidates failing in clinical trials. Our mission is to democratize and accelerate drug discovery by providing an AI-driven, end-to-end SaaS platform that integrates the entire workflow, from disease–gene prioritization to virtual clinical trials. Our Agentic AI Platform brings together multiple specialized agents for omics analysis, structure prediction, molecule generation, docking, ADMET profiling, and trial simulations into a single, unified system. Unlike existing siloed or prohibitively expensive solutions, our platform is affordable, cloud-based, and designed for startups, SMEs, universities, and biotech labs. With blockchain-enabled secure data curation and explainable AI dashboards, we ensure compliance, transparency, and trust in biomedical research. The global AI drug discovery market is projected to reach $25–30 billion by 2030, with a $2–3 billion opportunity in India. In the short term, Biotech Wallah targets a $50–100M segment through universities, startups, and labs adopting AI-powered discovery tools. We have already secured recognition with a $5,000 innovation reward from Harvard Medical School, and are building our MVP with modules like OmicsAgent, StructureAgent, and DockingAgent. Backed by collaborations with leading academic and industry partners, Biotech Wallah is on track to reduce drug discovery costs and timelines by up to 70%, making cutting-edge therapeutics more accessible worldwide.

Written by the company on its public Startup India profile. Not verified by us.